Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
July 18, 2019 12:40 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, July 18, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
June 27, 2019 12:18 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, June 27, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
June 05, 2019 12:42 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering
June 04, 2019 18:01 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, June 04, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline...
Cotinga Pharmacueticals Announces Closing of Unit Offering
May 22, 2019 17:26 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, May 22, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
May 08, 2019 11:10 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results
April 05, 2019 13:18 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, April 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering
March 19, 2019 11:00 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline...
Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
February 26, 2019 11:08 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2
January 29, 2019 10:21 ET
|
Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...